BeyondMold

SCIENCE MONOGRAPH

BEYOND MOLD SERIES

The Sentinel Mucosa

The Nasal Microbiome as a Site of Lost Immune Tolerance — and the Case for Retiring MARCoNS-Directed Therapy

In the CDR/ISR$_{mt}$ framework, nasal dysbiosis is best read as a terrain modifier held in place by the host's danger state — not as an upstream driver requiring targeted antimicrobial attack.

Andrew Heyman, MD, MHSA

Integrative & Metabolic Medicine

BEYOND MOLD · 2026

CONTENTS

The Nasal Microbiome as a Site of Lost Immune Tolerance

Why the CIRS field's focus on culturing and eradicating "MARCoNS" rests on a near-universal commensal, a correlational biomarker link, and a mechanistic claim that does not match palytoxin's pharmacology — and how, in the CDR/ISR$_{mt}$ model, the nose is better read as a sentinel mucosa whose health is defined by immune tolerance, not by any single organism.

ABSTRACT

Abstract

Within the CIRS tradition, the nasal cavity has been framed almost entirely through a single organism — the multiple antibiotic-resistant coagulase-negative staphylococcus, or MARCoNS — and a single therapeutic imperative: culture it, then eradicate it with topical antibiotics. This monograph argues that the emphasis is misplaced on both mechanistic and clinical grounds. First, the specific claim that MARCoNS releases a palytoxin-like polycyclic ether that acts systemically on the mitochondrial ribosome does not survive contact with the actual pharmacology of palytoxin, which is a plasma-membrane sodium-pump toxin of marine origin with no credible biosynthetic pathway in a nasal commensal. Second, the broader claim that a positive deep-nasal culture identifies a discrete pathogen driving illness is not supported by the microbiology: coagulase-negative staphylococci are near-universal nasal residents, and several of them are protective members of the community that excludes true pathobionts. What the nose actually represents is a sentinel mucosal surface whose health is defined not by the presence or absence of any one taxon but by the integrity of immune tolerance — the barrier, the secretory and antimicrobial-peptide defenses, the regulatory cellular tone, and the protective commensal consortium that together maintain a local "all-safe" state. In the Cell Danger Response / mitochondrial Integrated Stress Response (CDR/ISRmt) framework, nasal dysbiosis is best read as a terrain modifier held in place by the host's danger state, not as an upstream driver requiring targeted antimicrobial attack. Restoring normal flora belongs in the framework — but as an ecological, fortify-phase objective sequenced after the danger signal resolves, not as an early "killthe-bug" step.

SECTION ONE

The Problem: A Field Organized Around One Culture Result

The standard CIRS account of the nose is compact and has been remarkably durable. It holds that most patients with biotoxin-associated illness harbor, deep in the posterior nasal spaces, a biofilm-dwelling population of coagulase-negative staphylococci resistant to two or more antibiotic classes; that these organisms secrete hemolysins and exotoxins that cleave α-melanocyte-stimulating hormone (α-MSH), suppress regulatory T-cell populations, and sustain a pro-inflammatory cytokine tone; and that recovery therefore requires their eradication, classically with a compounded BEG spray (bactroban–EDTA–gentamicin), often with adjunctive rifampin, followed by re-culture to document clearance. The difficulty is not that any single element of this account is impossible. It is that the load-bearing claims are supported far more thinly than their prominence in the protocol implies, and that the framing commits a categorical error about what a nasal culture can tell you. Three problems deserve to be stated plainly. The organism is near-universal. Coagulase-negative staphylococci (CoNS) are a defining component of normal human skin and nasal flora. In practice, deep nasal culture returns CoNS in essentially everyone sampled; the "MARCoNS" designation is then generated by layering an antibiotic-resistance criterion on top of a near-ubiquitous commensal. A test that is positive in most people it is applied to

— patients and controls alike — cannot, by itself, identify a disease-specific pathogen. This is the classic problem of the innocent bystander: a normal resident is cultured, found, and blamed. The evidence is largely correlational and largely in-house. The foundational MARCoNS–α-MSH association derives principally from observational and conference-level work within the originating research program rather than from independent, controlled replication. The most recent and most quantitatively serious contribution — a 2026 retrospective cohort analysis — reports that patients who were MARCoNSnegative at follow-up had higher circulating α-MSH than those who remained positive, but explicitly frames this as an association warranting prospective study, and notably found no corresponding relationship for VIP or MMP-9. An association between a culture status and a single neuropeptide, in a retrospective design, is a hypothesis-generating finding. It is not evidence that the organism is driving the illness. The signature mechanistic claim is not biochemically viable. The most specific version of the pathogenicity argument — that MARCoNS releases a palytoxin-like polycyclic ether that interferes systemically with the mitochondrial ribosome — does not hold, for the reasons set out next.

> **Key point.** A near-universal commensal, a correlational biomarker link, and a mechanistic claim that does not match the toxin's known pharmacology are a weak foundation for a mandatory, antibiotic-based treatment step. Restoring a healthy nasal ecology may still matter; attacking "MARCoNS" specifically is a different proposition, and the justification for it is slender.

SECTION TWO

The Palytoxin–Mitoribosome Claim: Anatomy of a Category Error

The claim can be stated fairly: that coagulase-negative staphylococci in the nasal biofilm elaborate a palytoxin — a large polycyclic (polyether) marine toxin — and that this compound produces a systemic effect on the mitochondrial ribosome, thereby linking a local nasal colonizer to global mitochondrial and translational dysfunction. It is an attractive story because it appears to bridge the nose to the mitochondrion in one step. It contains at least three independent errors. Error one: palytoxin does not act on the mitoribosome. Palytoxin is one of the best-characterized nonpeptide toxins in pharmacology, and its mechanism is not in dispute. It binds the plasma-membrane sodium–potassium ATPase (Na+ /K+ -ATPase) with picomolar affinity and converts that ion pump into an open, non-selective cation channel. The consequence is uncontrolled K+ efflux, Na+ influx, membrane depolarization, secondary Ca2+ entry, and a cascade of downstream effects including hemolysis. This is a plasma-membrane, ion-pump mechanism. The mitochondrial ribosome — a distinct organellar machine that translates the thirteen mtDNA-encoded oxidative-phosphorylation subunits — is not palytoxin's target, is not its site of action, and does not figure in its established pharmacology. Error two: the biosynthesis is implausible in a staphylococcus. Palytoxin is a marine natural product of extraordinary size (molecular weight ≈ 2,680; among the largest non-polymeric natural products known), originating in zoanthids of the genus Palythoa and in Ostreopsis dinoflagellates. Its production reflects the enormous, specialized polyketide-

type biosynthetic apparatus characteristic of those marine eukaryotes. There is no credible evidence that a coagulase-negative staphylococcus — a small-genome Gram-positive commensal of human skin and nares — carries the biosynthetic machinery to make palytoxin or a genuine palytoxin congener. Error three: local colonization is treated as systemic exposure. Even setting the first two problems aside, a biofilm confined to the posterior nasal recess is not a plausible source of a systemically distributed, picomolar-potent ion-channel toxin acting on distant tissues. The known routes of human palytoxin intoxication are ingestion of contaminated seafood and inhalation or cutaneous contact during marine exposure — not commensal nasal carriage.

> **Key point.** The palytoxin–mitoribosome claim is a triple category error: it assigns the wrong mechanism (ion pump, not mitoribosome), to the wrong organism (a marine eukaryote's toxin, not a nasal staphylococcus's), acting at the wrong scale (a distant systemic effect from a local commensal biofilm). It should be retired from the framework, not softened.

Retiring the claim does not require asserting that the nasal biofilm is inert. It requires only that we stop explaining nasal contributions to illness with a mechanism that is biochemically false, and instead reason about the nose the way the mucosal immunology and microbial-ecology literature actually supports.

SECTION THREE

What the Nose Actually Is: The Sentinel Mucosa

The nasal cavity is not primarily a culture site. It is an immunological organ — the first mucosal checkpoint of the respiratory tract, continuously sampling the inhaled world and continuously deciding what to tolerate and what to repel. Its health is a property of immune tolerance, not of sterility. Four interlocking layers maintain that tolerance: The physical and chemical barrier. A tight-junction epithelium, a mucin gel layer, and mucociliary clearance physically exclude and expel particulates, allergens, spores, and microbes. Secretory and antimicrobial defense. Secretory IgA (SIgA) provides antigen-specific immune exclusion at the surface, while host antimicrobial peptides — β -defensins, the cathelicidin LL-37, lysozyme, lactoferrin — provide broad, tunable chemical defense that shapes which organisms persist. Regulatory cellular tone. Tolerogenic dendritic cells and regulatory T cells hold the mucosa in a calibrated, non-inflammatory posture, permitting commensal residence and harmless antigen exposure without triggering a full inflammatory program. The protective commensal consortium. A stable community of beneficial residents occupies niche and resources, produces its own antimicrobials, and actively excludes pathobionts. Lost tolerance is the failure of these layers acting together: a breached or inflamed barrier, depleted SIgA and antimicrobial-peptide reserve, a shift from regulatory to inflammatory cellular tone, and a collapse of the protective consortium in favor of a dominant pathobiont. Dysbiosis, in other words, is not a synonym for "a bad bug is present." It is the ecological signature of a mucosa that has lost its tolerant, self-regulating state. This relocates the clinical target. The question is not "is a resistant CoNS present?" — it almost always is. The question is "has this mucosa lost tolerance, and what host state is holding that loss in place?"

SECTION FOUR

The Protective Consortium — and the Coagulase-Negative Irony

The affirmative microbiology of the healthy nose is now reasonably well described, and it inverts the CIRS intuition in an important way. A healthy anterior-nares and nasopharyngeal community is typically populated by Corynebacterium species, Dolosigranulum pigrum, Moraxella, Cutibacterium, and commensal staphylococci including Staphylococcus epidermidis. Across independent cohorts, higher abundance of Corynebacterium and Dolosigranulum is associated with respiratory health and with colonization resistance against genuine pathobionts — most importantly Staphylococcus aureus, and also Streptococcus pneumoniae. Large-scale nasal-microbiome analyses consistently show S. aureus persistence to be negatively associated with Corynebacterium species, Dolosigranulum pigrum, Moraxella, and S. epidermidis: where the protective consortium is strong, the pathobiont is rare or absent; where the consortium collapses, the pathobiont dominates. The mechanisms are increasingly concrete rather than hand-waving:

Direct antimicrobials. The nasal commensal Staphylococcus lugdunensis produces lugdunin, a cyclic peptide antibiotic that suppresses S. aureus and can induce host antimicrobial peptides; carriers show markedly lower S. aureus colonization. Nutrient (iron) competition. The nose is iron-limited. Corynebacteria and other commensals engage in siderophore "piracy," consuming the iron-scavenging siderophores S. aureus needs and throttling its growth in an iron-dependent manner. Competitive exclusion. Corynebacterium species secrete factors that impair pathogen adherence to respiratory epithelium and reduce S. aureus and S. pneumoniae infection in animal and cell models. Here is the irony that should reorganize the clinical conversation. Coagulase-negative staphylococci are not a uniform threat; several are core protective members of this consortium. S. epidermidis is one of the community's stabilizing commensals and a source of anti-S. aureus activity; S. lugdunensis — itself coagulasenegative — is the producer of lugdunin. A therapeutic strategy that broadly targets "coagulase-negative staph in the deep nose" with topical antibiotics is therefore not obviously restoring an ecology. It risks depleting the very organisms whose presence predicts exclusion of the true pathobiont, while imposing selection pressure that favors resistant survivors.

> **Key point.** In the nose, "coagulase-negative staph" is not a diagnosis. It spans protective commensals (S. epidermidis, S. lugdunensis) and, at most, context-dependent opportunists. Treating the category as a target confuses the guardians with the intruder.

SECTION FIVE

Dysbiosis as Lost Tolerance, Not as a Named Culprit

If a specific organism deserves clinical respect in the nose, it is S. aureus, not "MARCoNS." A nasal community can be usefully described as existing in one of two broad states: a diverse, consortium-rich state in which S.

aureus is rare or absent, and a dysbiotic, S. aureus-dominated state in which the pathobiont shapes the community and displaces protective members. The dominance state — loss of Corynebacterium/Dolosigranulum/epidermidis, expansion of an inflammatory pathobiont, biofilm consolidation, barrier disruption — is what "dysbiosis" should mean here. Crucially, this state is not self-explanatory. Whether a given host tips into S. aureus dominance is only modestly explained by host genetics or exposure alone; the balance of commensal partners and the host's mucosal regulatory tone are decisive. A mucosa with intact SIgA, ample antimicrobial-peptide reserve, tolerogenic cellular tone, and a strong consortium resists the tip. A mucosa whose tolerance machinery has been degraded — by chronic antigenic and biotoxin load, by systemic inflammation, by depletion of regulatory tone — does not. Dysbiosis is the readout of that degraded terrain. This is precisely why a culture result, read in isolation, is uninformative about causation: the organism recovered from a dysbiotic nose is a passenger of the host state as often as it is a driver of it — and in the specific case of resistant CoNS, frequently neither driver nor even passenger, but a normal resident mislabeled.

SECTION SIX

Reframing the Nose in the CDR / ISRmt Model

The Cell Danger Response (CDR) and its mitochondrial Integrated Stress Response (ISRmt) provide the correct level of explanation. In this framework, chronic illness after water-damaged-building exposure is not a collection of discrete infections to be individually eradicated; it is a persistent, self-sustaining danger state in which cells hold a defensive posture long after the initiating exposure. The governing question throughout is load over reserve: illness persists when cumulative load exceeds the reserve available to resolve it. The nasal mucosa fits this model cleanly as a terrain, and nasal dysbiosis as a terrain modifier — a downstream, locally expressed feature of the systemic danger state, not an upstream cause of it. Purinergic tone and the local "all-safe" signal. Loss of mucosal tolerance is, mechanistically, partly a purinergic phenomenon. A danger-state mucosa sustains elevated extracellular ATP (eATP) and P2X7 signaling — a pro-inflammatory, alarm-dominant tone — and a relative failure of the CD39/CD73 ectoenzyme axis that normally hydrolyzes eATP to adenosine and re-establishes an anti-inflammatory, tolerogenic "allsafe" surface. A mucosa stuck in purinergic alarm cannot maintain the regulatory tone a protective consortium requires. Dysbiosis is what an alarm-locked mucosa grows, not what causes the alarm. The α-MSH correlation, reinterpreted. The 2026 observation that MARCoNS clearance tracks with higher α-MSH is more parsimoniously explained by shared upstream causation than by the organism driving the peptide. α-MSH is a neuroendocrine index of restored regulatory tone. When the systemic CDR resolves and neuroendocrine "all-safe" signaling recovers, two things happen together: α-MSH rises and the mucosal terrain normalizes, so the colonizer recedes on re-culture. The correlation is real; the causal arrow implied by the protocol — that killing the organism raises the peptide — is the least supported reading of it. That VIP and MMP-9 did not track with clearance is consistent with this: clearance is a marker of host recovery, not its engine. Phenotype mapping. Nasal tolerance loss is most salient in the phenotypes where immune regulation and the all-safe signal are most impaired. Phenotype C — Worn-Out Defender (CDR2-Immune): the immuneexhaustion phenotype, in which depleted mucosal reserve most directly permits consortium collapse and pathobiont expansion. Phenotype D — Closed Gate (CDR3-Blocked): the phenotype defined by a failed neuroendocrine all-safe signal, where restoring tolerance — including at the

mucosa — depends on relieving the ISR brake (Axis 1) and restoring the all-safe signal via VIP (Axis 2). A closed gate is, among other things, a mucosa that cannot re-establish tolerance no matter which organism is cultured or cleared.

> **Key point.** In the CDR/ISRmt model, the nose is terrain, dysbiosis is a terrain modifier, and MARCoNS is a marker of a tolerance-depleted mucosa — downstream of the danger state, held in place by it. The organism is a symptom of the terrain, not the lever that moves it.

SECTION SEVEN

Clinical Implications and Sequencing

Reframing the nose as a tolerance organ changes what we do, and — as importantly — when we do it. The sequencing rules resolve before fortify and engine before safety apply directly. Retire routine, culture-triggered MARCoNS eradication as a mandatory early step. A positive resistant-CoNS culture, absent a defined S. aureus-dominant pathology, does not by itself justify topicalantibiotic eradication. The step imposes real costs — disruption of protective commensals, selection for resistance, patient burden, Herxheimer-type flares — for a benefit resting on correlational data and a discredited mechanism. Do not fortify the terrain while the danger signal is active. Resetting the mucosa — by killing organisms or seeding "good" flora — while the systemic CDR remains unresolved is fortifying against an active brake; the dysbiosis will be reconstituted by the host state. Ecological restoration belongs in the fortify phase, after the danger signal is relieved. Restore the host, and the terrain follows. The primary levers are the framework's own: reduce load (genuine remediation first; appropriate binders), resolve the CDR/ISRmt state, and restore neuroendocrine all-safe tone — the VIP and α-MSH axis — which is also the tone that re-establishes mucosal tolerance. When restoring flora is indicated, do it ecologically, not antibiotically. "Restore normal flora" and "eradicate a named organism" are opposite operations. Ecological restoration means supporting the protective consortium and the barrier/antimicrobial-peptide reserve, reducing pathobiont dominance where it genuinely exists, and rebuilding the tolerant surface. Reserve targeted antimicrobial therapy for defined pathology. Genuine, characterized S. aureusdominant disease — clinical rhinosinusitis with corroborating findings, not merely a resistant-CoNS culture — is a real, evidence-based target and should be treated as such. Conflating that with routine "MARCoNS clearance" has done the field a disservice. Key point. The nose is fortified last, not attacked first. Resolve the danger state and restore the host's all-safe tone; the mucosal terrain, including its microbial ecology, largely re-regulates in train. Reserve targeted antimicrobial therapy for defined S. aureus pathology, not for a culture label.

SECTION EIGHT

Summary

The CIRS tradition has over-weighted a single nasal culture result. The “MARCoNS” designation layers a resistance criterion onto a near-universal commensal, and its link to illness rests on correlational, largely in-house data. The signature mechanistic claim — a palytoxin-like polycyclic ether acting on the mitoribosome — is a triple category error (wrong mechanism, wrong organism, wrong scale) and should be retired outright.

The nose is a sentinel mucosal organ whose health is defined by immune tolerance: barrier integrity, SIgA and antimicrobial-peptide reserve, regulatory cellular tone, and a protective commensal consortium. That consortium (Corynebacterium, Dolosigranulum, Moraxella, commensal staphylococci) actively excludes true pathobionts. Several coagulase-negative staphylococci — S. epidermidis, S. lugdunensis — are protective, not threats; broadly targeting “CoNS” risks depleting the guardians. Dysbiosis is the ecological signature of a mucosa that has lost tolerance, typically an S. aureus-dominant state, and is a readout of a degraded terrain rather than a self-explanatory cause. In the CDR/ISRmt model, nasal dysbiosis is a terrain modifier held in place by the systemic danger state — most relevant to Phenotypes C and D — and the α-MSH–clearance correlation is better read as shared upstream host recovery than organism-driven causation. Clinically: retire routine culture-triggered eradication; resolve before fortify; restore the host’s all-safe tone (VIP/α-MSH); restore flora ecologically and late; reserve targeted antimicrobial therapy for defined S. aureus pathology.

REFERENCES

References

Organized by section. Conference and internal-series items should be reconciled against the master citation apparatus during typesetting.

MARCoNS, α-MSH, and coagulase-negative staphylococci

Shoemaker RC, Hudnell K, House D, Domenico P. Association of nasal carriage of methicillin-resistant and multiple antibiotic-resistant coagulase-negative staphylococci with deficiency of α-melanocyte-stimulating hormone in chronic fatigue syndrome. American Society for Microbiology, 2003 (conference)

Retrospective cohort analysis of MARCoNS clearance and circulating α-MSH in patients evaluated for CIRS. Frontiers in Endocrinology, 2026; article 1728408.

Becker K, Heilmann C, Peters G. Coagulase-negative staphylococci. Clinical Microbiology Reviews, 2014;27(4):870– 926.

Palytoxin pharmacology

Rossini GP, Bigiani A. Palytoxin: membrane mechanisms of action. Toxicon, 2011;57(3):429–439.

Habermann E. Palytoxin acts through Na+ ,K+ -ATPase. Toxicon, 1989;27(11):1171–1187.

Structural basis for palytoxin conversion of the Na+ /K+ pump into a cation channel. PNAS, 2025;122.

Pelin M, et al. Palytoxin cytotoxicity and Na+ /K+ -ATPase isoform sensitivity in human cells. Marine Drugs / Toxins, 2013–2018.

Nasal microbiome ecology and colonization resistance

Zipperer A, Konnerth MC, Laux C, et al. Human commensals producing a novel antibiotic (lugdunin) impair pathogen colonization. Nature, 2016;535:511–516.

Nasal S. lugdunensis antagonizes S. aureus via siderophore piracy. PMC, 2024 (PMC11495082)

Nasal commensals reduce S. aureus proliferation by restricting siderophore availability. PMC, 2024 (PMC11296517)

Airway Corynebacterium interfere with S. pneumoniae and S. aureus and express pathogen-selective secreted factors. PMC, 2025 (PMC11834435)

Computational and in vitro evaluation of commensal treatments for nasal S. aureus decolonization. PNAS, 2025;122.

Liu CM, Price LB, Hungate BA, et al. Staphylococcus aureus and the ecology of the nasal microbiome. Science Advances, 2015;1(5):e1400216.

Large-scale characterisation of the nasal microbiome redefines S. aureus colonisation status. Nature Communications, 2025;16.

Mucosal tolerance, CDR / ISRmt, and purinergic signaling

Krismer B, Weidenmaier C, Zipperer A, Peschel A. The commensal lifestyle of Staphylococcus aureus and its interactions with the nasal microbiota. Nature Reviews Microbiology, 2017;15:675–687.

Naviaux RK. Metabolic features of the cell danger response. Mitochondrion, 2014;16:7–17.

Naviaux RK. Perspective: Cell danger response biology. Mitochondrion, 2020;51:40–45.

Antonioli L, Pacher P, Vizi ES, Haskó G. CD39 and CD73 in immunity and inflammation. Trends in Molecular Medicine, 2013;19(6):355–367.

Beyond Mold Science Monograph Series — companion monographs: The Architecture of Reserve; Tolerance Threshold; the gut-barrier cascade monograph (internal cross-references).